Low frequency of EGFR mutations in pleural mesothelioma patients, Cologne, Germany

Applied Immunohistochemistry and Molecular Morphology

Volumn 23, Issue 2, 2015, Pages 118-125

  Schildgen, Verena ^a   Pabst, Olga ^a   Tillmann, Ramona Liza ^a   Lüsebrink, Jessica ^a   Schildgen, Oliver ^a   Ludwig, Corinna ^a   Brockmann, Michael ^a   Stoelben, Erich ^a  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

EGFR; Germany; mesothelioma; mutations

Indexed keywords

ADENINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GUANINE; THYMIDINE; CODON; EGFR PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; EXON; FEMALE; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; GERMANY; HUMAN; HUMAN TISSUE; MALE; MIDDLE AGED; PLEURA MESOTHELIOMA; POINT MUTATION; PRIORITY JOURNAL; PYROSEQUENCING; VERY ELDERLY; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETICS; HIGH THROUGHPUT SEQUENCING; MESOTHELIOMA; MUTATION; PLEURAL NEOPLASMS;

AGED; AGED, 80 AND OVER; CODON; FEMALE; GENE FREQUENCY; GERMANY; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; MUTATION; PLEURAL NEOPLASMS; POLYMORPHISM, GENETIC; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84923826942     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PDM.0b013e3182a3645e     Document Type: Article

References (12)

1. Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7:169-181
2. Zhang Z, Wriggers W. Polymorphism of the epidermal growth factor receptor extracellular ligand binding domain: the dimer interface depends on domain stabilization. Biochemistry. 2011;50: 2144-2156
3. Foster JM, Radhakrishna U, Govindarajan V, et al. Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma. World J Surg Oncol. 2010;8:88
4. Hartmannn JT, Bokemeyer C. Benigne und maligne Mesotheliome: Definition. 2002. Available at: http://www.onkodin.de/e2/e7097/ e7098/. Accessed January 2013
5. Moore AJ, Parker RJ, Wiggins J. Malignant mesothelioma. Orphanet J Rare Dis. 2008;3:34
6. Nakano T. Current therapies for malignant pleural mesothelioma. Environ Health Prev Med. 2008;13:75-83
7. Cortese JF, Gowda AL, Wali A, et al. Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma. Int J Cancer. 2006;118:521-522
8. Kobayashi M, Takeuchi T, Ohtsuki Y. Establishment of three novel human malignant pleural mesothelioma cell lines: morphological and cytogenetical studies and EGFR mutation status. Anticancer Res. 2008;28(1A):197-208
9. Velcheti V, Kasai Y, Viswanathan AK, et al. Absence of mutations in the epidermal growth factor receptor (EGFR) kinase domain in patients with mesothelioma. J Thorac Oncol. 2009;4:559
10. Enomoto Y, Kasai T, Takeda M, et al. Epidermal growth factor receptor mutations in malignant pleural and peritoneal mesothelioma. J Clin Pathol. 2012;65:522-527
11. Barbieri F, Wurth R, Favoni RE, et al. Receptor tyrosine kinase inhibitors and cytotoxic drugs affect pleural mesothelioma cell proliferation: insight into EGFR and ERK1/2 as antitumor targets. Biochem Pharmacol. 2011;82:1467-1477
12. Favoni RE, Pattarozzi A, Lo Casto M, et al. Gefitinib targets EGFR dimerization and ERK1/2 phosphorylation to inhibit pleural mesothelioma cell proliferation. Curr Cancer Drug Targets. 2010;10:176-191.